How is POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal plasma‑cell disorder, Skin changes) diagnosed and managed?

POEMS Syndrome: Diagnosis and Management

For POEMS syndrome diagnosis, you must confirm three major criteria (including both polyneuropathy AND clonal plasma cell disorder as mandatory) plus at least one minor criterion, with radiation therapy as first-line for localized disease and systemic therapy (melphalan-dexamethasone or lenalidomide-dexamethasone) for disseminated disease, while avoiding neurotoxic agents like bortezomib and thalidomide. 1

Diagnostic Criteria

The diagnosis requires a systematic approach with specific mandatory elements:

Major Criteria (need 3, with first 2 mandatory):

• Polyradiculoneuropathy (mandatory)
• Clonal plasma cell disorder (mandatory, almost always λ light chain restriction)
• Elevated vascular endothelial growth factor (VEGF)
• Sclerotic bone lesions
• Castleman disease

Minor Criteria (need ≥1):

• Endocrinopathy
• Organomegaly (hepatomegaly, splenomegaly, lymphadenopathy)
• Characteristic skin changes (hyperpigmentation, hypertrichosis, hemangiomas)
• Papilledema
• Extravascular volume overload (pleural effusion, ascites, edema)
• Thrombocytosis

1

Required Diagnostic Workup

Perform these specific tests 1:

• Iliac crest bone marrow biopsy or aspirate
• Serum and urine immunofixation with free light chains
• Serum VEGF levels (characteristically markedly elevated)
• Abdomen and pelvis CT scan
• Whole body X-rays and FDG-PET scan
• Pulmonary function tests
• Cardiac ultrasound
• Endocrine laboratory panel
• Nerve conduction studies/EMG

Common diagnostic pitfall: POEMS is frequently misdiagnosed as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), particularly when patients present with progressive neuropathy. The key distinguishing features are elevated VEGF, sclerotic bone lesions, and the presence of monoclonal protein. 2, 3

Risk Stratification

Identify high-risk features that predict worse outcomes:

• Low serum albumin
• Advanced age
• Pleural effusion
• Pulmonary hypertension
• Reduced eGFR (estimated glomerular filtration rate)

2, 3

Treatment Algorithm

Step 1: Determine Disease Extent

Localized Disease (solitary or limited sclerotic bone lesions without bone marrow involvement):

• First-line: Radiation therapy to the affected lesion(s)
• Achieves 97% 4-year overall survival and 52% 4-year failure-free survival
• Results in improvement in 50-70% of patients
• This is the preferred approach when feasible 1

Disseminated Disease (diffuse sclerotic lesions or bone marrow involvement):

• Proceed to systemic therapy (Step 2)
• Large bone lesions may require adjuvant radiation 6 months after chemotherapy 1

Step 2: Systemic Therapy Selection

For transplant-eligible patients (younger, good organ function):

• Preferred: Autologous stem cell transplantation (ASCT)
• Achieves 100% clinical improvement rate
• Results in 98% PFS at 1 year, 94% at 2 years, and 75% at 5 years
• Consider induction therapy before transplantation to improve stem cell harvest 1, 2, 4

For non-transplant candidates or older patients:

First-line options 1, 2:

1. Melphalan-dexamethasone: 81% hematologic response, 100% show some neurologic improvement
2. Lenalidomide-dexamethasone: Majority of patients respond, manageable toxicity profile
3. Cyclophosphamide-dexamethasone: 50% clinical improvement

Agents to AVOID or use with extreme caution:

• Bortezomib: Not recommended as first-line due to high risk of worsening pre-existing neuropathy 1
• Thalidomide: Risk of induced/exacerbated neuropathy outweighs benefits 1

Emerging option:

• Daratumumab-based combinations: Show promise in case series but require more data 2

Step 3: Monitor Response

Critical timing considerations:

• Significant lag exists between successful therapy and neurologic response
• Maximum neurologic improvement expected after 2-3 years
• Optimal response on FDG-PET may lag by 6-12 months
• VEGF levels normalize with effective treatment 1

If disease progresses 3-6 months after radiation therapy: Switch to systemic therapy 3

Special Considerations

Supportive care is essential:

• Manage extravascular volume overload (diuretics, paracentesis if needed)
• Address endocrinopathies with hormone replacement
• Treat thrombocytosis if symptomatic or extreme
• Monitor for thromboembolic events (increased risk)

Atypical presentations exist: Some patients may have kappa (rather than lambda) restriction or subclinical polyneuropathy detectable only on EMG. Maintain high clinical suspicion when other features are present. 5

The therapeutic goal is to target the underlying plasma cell clone, not VEGF directly. Bevacizumab (anti-VEGF antibody) reduces VEGF levels but has been associated with several deaths and is not recommended. 1